卡培他滨联合奥沙利铂治疗晚期胃癌的近期疗效观察

目的观察卡培他滨联合奥沙利铂方案（XELOX）治疗晚期胃癌的近期疗效及毒副反应。方法28例晚期胃癌患者采用XELOX方案化疗：奥沙利铂（L—OHP）135mg／m^2、卡培他滨（Xeloda）;1000mg／mzbid，d1～14，21天一周期，两周期后评价疗效。结果28例均可评价疗效，中位TTP为6．5月，中位MST为11．9月，总有效率为53．6％，临床获益率为71．4％；主要不良反应为手足综合征、外周神经麻木、恶心呕吐及骨髓抑制等，均能耐受。结论卡培他滨联合奥沙利铂方案（XELOX）治疗晚期胃癌疗效确切，毒副反应轻，安全性好，可以作为一般状况较差的晚期及复发转移胃癌患者化疗的选择。

Curative effect of Oxaliplatin combined with Capeeitabine in treatment for advanced gastric cancer

Objective To observe and evaluate the effects and toxicity of Oxaliplatin combined with Capecitabine(XELOX) in the treatment for the advanced gastric cancer.Methods 28 patients with advanced gastric cancer were treated with Oxaliplatin(135 mg/m2) combined with Capoeitabine (1000mg/m2) divided in two daily doses given from dl to d14.Evaluation was performed at the end of 2 cycles.Results All of these 28 patients were evaluated for response,with a total response rate (RR) of 53.6％.The median progression-free survival was 6.5 months and the median overall survival time was 11.9months.The most common adverse effects were hand-foot syndrome,peripheral nervous anaesthesia,gastrointestinal toxicities and myelosuppression.Conclusion Oxaliplatin combined with Capecitabine is safe and effective for advanced gastric cancer treatment,with tolerable side effects.